Literature DB >> 19700946

Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial).

Clive Ballard1, Richard Brown, Jane Fossey, Simon Douglas, Paul Bradley, Judith Hancock, Ian A James, Edmund Juszczak, Peter Bentham, Alistair Burns, James Lindesay, Robin Jacoby, John O'Brien, Roger Bullock, Tony Johnson, Clive Holmes, Robert Howard.   

Abstract

BACKGROUND: Good practice guidelines state that a psychological intervention should usually precede pharmacotherapy, but there are no data evaluating the feasibility of psychological interventions used in this way.
METHODS: At the first stage of a randomized blinded placebo-controlled trial, 318 patients with Alzheimer disease (AD) with clinically significant agitated behavior were treated in an open design with a psychological intervention (brief psychosocial therapy [BPST]) for 4 weeks, preceding randomization to pharmacotherapy. The therapy involved social interaction, personalized music, or removal of environmental triggers.
RESULTS: Overall, 318 patients with AD completed BPST with an improvement of 5.6 points on the total Cohen-Mansfield Agitation Inventory (CMAI; mean [SD], 63.3 [16.0] to 57.7 [18.4], t = 4.8, df = 317, p < 0.0001). Therapy worksheets were completed in six of the eight centers, with the key elements of the intervention delivered according to the manual for >95% of patients. More detailed evaluation of outcome was completed for the 198 patients with AD from these centers, who experienced a mean improvement of 6.6 points on the total CMAI (mean [SD], 62.2 [14.3] to 55.6 [15.8], t = 6.5, df = 197, p < 0.0001). Overall, 43% of participants achieved a 30% improvement in their level of agitation.
CONCLUSION: The specific attributable benefits of BPST cannot be determined from an open trial. However, the BPST therapy was feasible and was successfully delivered according to an operationalized manual. The encouraging outcome indicates the need for a randomized controlled trial of BPST.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19700946     DOI: 10.1097/JGP.0b013e3181b0f8c0

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  22 in total

1.  [Psychosocial interventions and caregiver support].

Authors:  M Hüll; I Wernher
Journal:  Nervenarzt       Date:  2010-07       Impact factor: 1.214

2.  A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia.

Authors:  Zahinoor Ismail; Chetachi A Emeremni; Patricia R Houck; Sati Mazumdar; Jules Rosen; Tarek K Rajji; Bruce G Pollock; Benoit H Mulsant
Journal:  Am J Geriatr Psychiatry       Date:  2013-01-02       Impact factor: 4.105

Review 3.  Current and emerging drug treatment options for Alzheimer's disease: a systematic review.

Authors:  Nathan Herrmann; Sarah A Chau; Ida Kircanski; Krista L Lanctôt
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

Review 4.  Music-based therapeutic interventions for people with dementia.

Authors:  Jenny T van der Steen; Mirjam C van Soest-Poortvliet; Johannes C van der Wouden; Manon S Bruinsma; Rob Jpm Scholten; Annemiek C Vink
Journal:  Cochrane Database Syst Rev       Date:  2017-05-02

5.  A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.

Authors:  D P Devanand; Gregory H Pelton; Karine Cunqueiro; Harold A Sackeim; Karen Marder
Journal:  Int J Geriatr Psychiatry       Date:  2010-12-28       Impact factor: 3.485

6.  The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.

Authors:  D P Devanand; Jacobo Mintzer; Susan Schultz; David Sultzer; Danilo de la Pena; Sanjay Gupta; Sylvia Colon; Corbett Schimming; Gregory H Pelton; Howard Andrews; Bruce Levin
Journal:  Am J Geriatr Psychiatry       Date:  2012-04       Impact factor: 4.105

7.  Treatment of Parkinson's disease psychosis.

Authors:  Kevin J Black
Journal:  Med Int Rev       Date:  2018-02-03

8.  Relapse risk after discontinuation of risperidone in Alzheimer's disease.

Authors:  D P Devanand; Jacobo Mintzer; Susan K Schultz; Howard F Andrews; David L Sultzer; Danilo de la Pena; Sanjay Gupta; Sylvia Colon; Corbett Schimming; Gregory H Pelton; Bruce Levin
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

Review 9.  Management of agitation and aggression associated with Alzheimer disease.

Authors:  Clive G Ballard; Serge Gauthier; Jeffrey L Cummings; Henry Brodaty; George T Grossberg; Philippe Robert; Constantine G Lyketsos
Journal:  Nat Rev Neurol       Date:  2009-05       Impact factor: 42.937

10.  Treatment of dementia with lewy bodies.

Authors:  Brendon P Boot; Eric M McDade; Scott M McGinnis; Bradley F Boeve
Journal:  Curr Treat Options Neurol       Date:  2013-12       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.